ÖZET
Yeni bir koronavirüsün (daha önce 2019-nCoV olarak bilinen Şiddetli akut solunum enfeksiyonu-koronavirüs-2) neden olduğu akut solunum yolu hastalığı, koronavirüs hastalığı 2019 (COVİD-19) Aralık 2019’da ortaya çıkmış ve daha sonra Çin, Japonya ve Güney Kore’den başlayarak Dünya genelinde hızlı bir yayılım göstermiştir. 30 Ocak 2020 itibariyle de Dünya Sağlık Örgütü COVİD-19 salgınını resmi olarak ilan etmiştir. COVİD-19’un klinik semptomlarına bakıldığında yüksek ateş, öksürük, yorgunluk gibi birçok semptomu vardır. Yaşlılarda ve kronik hastalıkları olanlarda bu hastalığın çok ağır geçtiği ve sitokin fırtınası ile akut solunum sıkıntısı sendromu (ARDS) gibi ciddi sonuçlara neden olduğu bildirilmektedir. Şu anda bilim insanları tarafından spesifik antiviral tedavi stratejisi bulunmaya çalışılmaktadır. Hidroksiklorokin, lopinavir/ritonavir, ribavirin, remdesivir ve favipiravir gibi çeşitli ilaçlar şu anda Dünya çapında COVİD-19 tedavisinde etkinliklerini ve güvenliklerini test etmek için klinik çalışmalarda uygulanmaktadır ve şimdiye kadar bazı umut verici sonuçlar elde edilmiştir. Bu derlemede, COVİD-19’a karşı potansiyel etkinliği olan ajanlar özet halinde sunulmaktadır.
References
1
Center JHCR. COVID-19 Map 2020. Available from: https://coronavirus.jhu.edu/map.html.
2
T.C. Sağlık Bakanlığı. T.C Sağlık Bakanlığı Korona Tablosu 2020. Available from: https://covid19.saglik.gov.tr/
3
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64-8.
4
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronaviruses-drug discovery and therapeutic options. Nature reviews Drug Discov 2016;15:327.
5
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a Review. JAMA 2020;323:1824-36.
6
T.C. Sağlık Bakanlığı. COVID-19 Erişkin Hasta Tedavisi. 2020. Available from: https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html p. 1-19.
7
T.C. Sağlık Bakanlığı. COVID-19. Çocuk Hasta Yönetimi ve Tedavisi. Available from: https://covid19.saglik.gov.tr/Eklenti/38596/0/covid-19rehbericocukhastayonetimivetedavipdf.pdf 2020. p. 1-5.
8
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67-9.
9
Aguiar AC, Murce E, Cortopassi WA, Pimentel AS, Almeida MM, Barros DC, et al. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 2018;8:459-64.
10
Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020;75:1667-70.
11
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. J Virol 2005;2:69.
12
Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001;20:137-40.
13
Wang L. Cell Res. the press; 2019.
14
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis 2003;3:722-7.
15
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. Avaialble from: ClinicalTrials.gov. Home 2020.
16
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020:105938.
17
Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020;38:379-81.
18
Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, et al. Efficacy and tolerability of lopinavir/ritonavir-and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol 2019;10:1472.
19
Cvetkovic RS, Goa KL. Lopinavir/ritonavir. Drugs 2003;63:769-802.
20
Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
21
Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-b1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19:81.
22
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Eng J Med 2020;382:1787-99.
23
Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35:e79.
24
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:449-63.
25
Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.
26
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discover Ther 2020;14:58-60.
27
Bosseboeuf E, Aubry M, Nhan T, Pina J, Rolain J, Raoult D, et al. Azithromycin inhibits the replication of zika virus. J Antivir Antiretrovir 2018;10:6-11.
28
Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 2015;1:317-26.
29
Bacharier L, Guilbert T, Mauger D, Boehmer S, Beigelman A, Fitzpatrick A, et al. National Heart, Lung, and Blood Institute’s AsthmaNet. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA 2015;314:2034-44.
30
Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrobi Agents 2020:105949.
31
ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Eng J Med 2020;382:929-36.
32
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:1-14.
33
Arena C. Coronavirus outbreak: Top coronavirus drugs and vaccines in development. Last Accessed Date: 26.03.2020. Available from: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs.
34
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
35
Türkiye Ulusal Alerji ve Klinik İmmünoloji Derneği. COVID-19 Tedavisinde Kullanılan İlaçlara Gelişen İstenmeyen İlaç Reaksiyonları 2020 Last Accessed Date: 26.03.2020. Avaialable from: https://www.aid.org.tr/covid-19-tedavisinde-kullanilan-ilaclara-gelisen-istenmeyen-ilac-reaksiyonlari/
36
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343.
37
Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.
38
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. Journal of medical virology. 2020.
39
Jie Z, He H, Xi H, Zhi Z. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:185-8.
40
Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020;105932(10.1016).
41
Golden EB, Cho H-Y, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 2015;38:E12.
42
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9:e00221-18.
43
Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019;11:326.
44
Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 2019;11:eaau9242.
45
Hsieh H-P, Hsu JT-A. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42.
46
Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-92.
47
Tsang K, Zhong NS. SARS: pharmacotherapy. Respirology 2003;8:S25-30.
48
Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clini Infect Dis 2020;70:1837-44.
49
McQuade B, Blair M. Influenza treatment with oseltamivir outside of labeled recommendations. Am J Health System Pharm 2015;72:112-6.
50
Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
51
Shiraki K. Antiviral drugs against alphaherpesvirus. Human Herpesviruses: Springer; 2018:103-22.
52
Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020;7:1-10.
53
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446-54.
54
Goldhill DH, te Velthuis AJ, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A 2018;115:11613-8.
55
Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S. Will there be a cure for Ebola? Ann Rev Pharmacol Toxicol 2017;57:329-48.
56
Rossignol J-F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 2014;110:94-103.
57
Cao J, Forrest JC, Zhang X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res 2015;114:1-10.
58
Rossignol J-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 2016;9:227-30.
